New combo aims to stop rare Cancer's return after surgery
NCT ID NCT06210490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a targeted drug called disitamab vedotin, given together with radiation therapy, can prevent cancer recurrence in people with HER2-positive upper tract urothelial cancer who are at high risk after surgery. About 60 participants will either receive the combination treatment or be closely watched. The study will track how long they remain cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Disitamab vedotin (a targeted antibody-drug conjugate) and radiotherapy
- What this could lead to
- If successful, this combination could offer a new option to reduce the chance of cancer returning after surgery for patients with HER2-positive upper tract urothelial cancer.
- What could go wrong
- This is a small, early-phase study with only 60 participants, so results may not apply broadly. The drug can cause side effects like nerve damage or low blood counts, and it is not yet proven to improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER URINARY TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists create new tools to fight rare urinary tract cancer
- One-Time bladder treatment after kidney surgery may stop cancer comeback
- Could chemo before surgery beat cancer better?
- New cancer gel shows promise for rare urinary tract tumors
- New drug combo aims to spare kidneys in High-Risk urinary tract cancer
- Major european study tests if Kidney-Saving surgery is safe for rare cancer